COMPANY:

ANGLE

"ANGLE plc...is pleased to announce that the European Patent Office has granted a European Patent for its innovative CellKeep™ slide. A formal communication has also been received from the United States Patent and Trademark Office indicating that grant of the equivalent US patent application is imminent."

"ANGLE plc...announce its participation at the American Association for Cancer Research (AACR) Annual Meeting, San Diego, US between 5 to 10 April 2024...ANGLE is presenting a poster entitled the 'Development and analytical validation of a novel assay for HER2 assessment on circulating tumor cells harvested using the Parsortix® system and incorporating BioView imaging technologies'."

"ANGLE plc...is pleased to announce its participation at the 14th European Breast Cancer Conference (EBCC) being held in Milan, Italy on 20 to 22 March 2024...ANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Portrait HER2 assay"

"ANGLE plc...is pleased to announce the publication of a peer-reviewed paper in a special issue of the journal - 'Current Issues in Molecular Biology' Special Issue: Advanced Solutions for Cancer Therapy...This peer-reviewed article brings together supporting evidence for the additional and complementary information that can be obtained from CTCs using the Parsortix® system, demonstrating the value of a dual analyte approach for both CTCs and ctDNA."

"ANGLE plc...is delighted to announce breakthrough results from DNA molecular analysis of cancer patient blood samples that provide a unique insight into the progression of each patient's cancer and how this may be treated...Combined DNA Next Generation Sequencing of CTCs and ctDNA from the same blood sample highlights potential for the Parsortix system to identify key variants (DNA mutations) missed by other approaches to help guide treatment decisions..."

"ANGLE plc...is delighted to announce that it has signed a contract with the global pharmaceutical company, Eisai Inc. ('Eisai')...Under the agreement, in a pilot study worth US $250,000 to ANGLE, ANGLE will provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 (human epidermal growth factor receptor 2) status in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701. Success in the pilot study offers the potential for multiple large scale follow-up studies."

"ANGLE plc...is delighted to announce the publication of breakthrough work by researchers at the University of New Mexico, US, into the role of CTC gene expression in the progression of melanoma brain metastasis. The researchers used the Parsortix system to harvest CTCs for analysis and concluded that '… gene expression in CTCs could be pivotal to prescribing more targeted treatment based on the needs of the patient.'"

"ANGLE plc...is delighted to announce the launch of its Portrait®+ CTC staining kit at the San Antonio Breast Cancer Symposium (SABCS)...This launch follows extensive development, optimisation and validation of the kit to provide advanced immunofluorescent (IF) staining of CTCs harvested from a patient blood sample by the Parsortix technology."

"ANGLE plc...is delighted to announce the launch of its Portrait® PD-L1 test for the evaluation of PD-L1 protein expression on CTCs following extensive development and optimisation. The test is provided as a service from ANGLE's Onc-ADaPT® GCP-compliant laboratories and is conducted by an expert team with over 10 years' experience in CTC analysis."

"ANGLE plc...is pleased to announce the publication of a study using the Parsortix system that sheds new light on the phenotypic characteristics of CTCs in Head and Neck Squamous Cell Carcinoma (HNSCC)...The study, conducted by researchers at the University of Birmingham, UK, demonstrates the feasibility of using mass cytometry, a powerful technique widely used for single cell analysis, for the comprehensive characterisation of CTCs captured by the Parsortix system in HNSCC patients."

"ANGLE plc...announces the publication of a study of disseminated tumour cells (DTCs) in bone marrow from breast cancer patients published in the International Journal of Molecular Sciences...Researchers at the University of Tübingen, Germany, used the Parsortix® system for the isolation and harvest of DTCs from bone marrow samples in 360 breast cancer patients (clinical stages I-IV) and compared results to the standard density centrifugation method for DTC detection."

"ANGLE plc...is pleased to announce its participation at the 6th Advances in Circulating Tumor Cells (ACTC) conference held in Greece from 20-23 September 2023...This included the presentation of nine posters showcasing the Parsortix® system in six cancer types across eight independent study centres."

"ANGLE plc...is pleased to announce the launch of its Portrait™ Flex CTC assay...The assay is provided as a service from ANGLE's Onc-ADaPT™ GCP-compliant laboratories and conducted by an expert team with over 10 years' experience in CTC analysis...The Portrait Flex assay has an analytical sensitivity...of >93%, and an analytical specificity...of >95% for both epithelial and mesenchymal markers."

"ANGLE plc...is delighted to announce that its first bespoke assay development customer, Artios Pharma (Artios), has signed a new contract to utilise two DNA Damage Response assays developed by ANGLE in a Phase 1 clinical trial expected to commence shortly...Artios selected ANGLE to develop immunofluorescence (IF) assays using its Parsortix system to detect two specific biomarkers expressed on circulating tumour cells (CTCs). The expression of the two biomarkers indicate the amount of DNA damage caused in a cell."

"ANGLE plc...is delighted to announce it has signed an agreement with BioView Ltd...to develop a liquid biopsy circulating tumor cell (CTC) HER2 assay for breast cancer utilising ANGLE's FDA cleared Parsortix® PC1 Clinical System to harvest CTCs and BioView's automated microscopy systems and software to detect and assess the HER2 expression and/or gene amplification in CTCs."

"ANGLE plc...is pleased to announce the presentation of a poster at the American Association for Cancer Research (AACR) annual meeting, in Orlando, Florida, United States, between 14-19 April 2023. The poster presents successful development work undertaken by ANGLE since FDA clearance to develop protocols to combine immunofluorescent (IF) staining for epithelial, mesenchymal and epithelial-to-mesenchymal (EMT) phenotype characterisation of circulating tumour cells (CTCs) with HER2 fluorescence in-situ hybridization (FISH) staining for gene amplification assessment on samples from blood processed using the Parsortix® system."

"ANGLE plc...is delighted to announce that it has signed a contract with a new customer, Crescendo Biologics Limited...Crescendo will use ANGLE's recently launched Portrait Flex assay in its ongoing Phase 1 clinical trial (NCT04839991) investigating the safety and efficacy of CB307, Crescendo's first-in-class prostate-specific membrane antigen (PSMA) x CD137 half-life extended bispecific, for the treatment of patients with PSMA positive solid tumours."

"ANGLE plc...is pleased to announce the presentation of two posters at the San Antonio Breast Cancer Symposium (SABCS), in San Antonio, Texas, United States, between 06-10 December 2022. The studies demonstrated the successful isolation and subsequent analysis of circulating tumour cells (CTCs) from Metastatic Breast Cancer (MBC) patient blood samples using the Parsortix® PC1 Clinical System."

"ANGLE plc...announce the publication of results from a multi-centre clinical study undertaken with The University of Texas MD Anderson Cancer Center, TX, Wilmot Cancer Institute, University of Rochester, NY, Robert H Lurie Comprehensive Cancer Center, Northwestern University, IL, and Norris Comprehensive Cancer Center, University of Southern California, CA, US. The Parsortix® system was used to enrich circulating tumour cells (CTCs) from 207 patients with metastatic breast cancer (MBC) with each patient providing two blood tubes allowing for testing of multiple downstream analytical techniques."

"ANGLE plc...is pleased to announce it presented results from a proof of concept study at the International Society of Liquid Biopsy meeting in Miami, Florida on 20-22 October 2022...The results show that removal of plasma from blood samples for circulating tumour DNA (ctDNA) analysis does not impact on the number or quality of circulating tumour cells (CTCs) which can be successfully isolated from the same sample using the Parsortix® system."

"ANGLE plc...is pleased to announce it has signed a distribution agreement with Promedeus s.r.o to enable and support the roll out of the FDA cleared and CE marked Parsortix® PC1 system across the Czech Republic for its intended use in metastatic breast cancer."

"ANGLE plc...is delighted to announce positive headline results from its ovarian cancer clinical verification study, demonstrating that a Parsortix® blood test can be used to determine if a woman is at risk of a malignant pelvic mass."

"ANGLE plc...is pleased to announce that the University of Birmingham has published the results of a study undertaken in head and neck squamous cell carcinoma (HNSCC) which characterised the epithelial-mesenchymal transition (EMT) status of circulating tumour cells (CTCs)...The study used the Parsortix® system to harvest CTCs from peripheral blood samples from 20 treatment-naïve HNSCC patients at baseline prior to surgery."

"ANGLE plc...is delighted to announce that its United States clinical laboratory team presented a new poster at the 100th American Society for Clinical Pathology (ASCP) meeting in Chicago, Illinois, USA between 7-9 September 2022. The poster, which describes the novel use of Papanicolaou (Pap) staining procedures with cells harvested from blood samples using the Parsortix® system, was selected as a finalist for a prestigious Blue Ribbon award for laboratory practice by ASCP judges."

"ANGLE plc...is delighted to announce the publication of results from a clinical study undertaken in partnership with the Wilmot Cancer Institute, University of Rochester, NY, US. The Parsortix® system was utilised for cancer detection in 183 women with a pelvic mass who had a range of benign and malignant conditions. The results have been published in the respected, high impact, journal Obstetrics & Gynecology ('The Green Journal')."

"ANGLE plc...is pleased to announce details of a new separate study...The study used the Parsortix® system to harvest CTCs from whole blood samples from 46 early-stage non-small cell lung cancer (NSCLC) patients, to analyse the expression of Metabolism-Related Genes (MRGs). Use of the biomarker-independent Parsortix system also allowed the researchers to investigate the association of MRG expression with epithelial and epithelial to mesenchymal transition (EMT) markers."

"ANGLE plc...is pleased to announce that the world-class research team led by Prof. Evi Lianidou at the National and Kapodistrian University of Athens, Greece, has recently published results of a study undertaken in early-stage non-small cell lung cancer (NSCLC), which demonstrates the benefit of analysing epigenetic alterations in circulating tumour cells (CTCs) to assess patient prognosis...The researchers used the Parsortix® system to isolate CTCs from 42 early-stage NSCLC patients for DNA methylation analysis."

"ANGLE plc...announce ground-breaking research by the world-class team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland. The study utilised the Parsortix® system to investigate the impact of sleep on the release of CTCs in preclinical models and 30 patients with breast cancer (21 with early stage and 9 with metastatic disease)...The Parsortix system provided biomarker-independent isolation and harvest of CTCs, CTC clusters and CTC-white blood cell (WBC) clusters."

"ANGLE plc...is delighted to announce that the Company has secured an additional contract with its first large-scale pharma services customer. The customer, a pharma company with numerous cancer drugs under development and revenues exceeding US$1 billion per annum, has again selected ANGLE's Parsortix® system to undertake longitudinal monitoring (i.e. before, during and after drug intervention) of patients with certain unresectable solid tumours in a new Phase Ib dose-escalation study using its investigational drug in combination with immuno-oncology agents."

"ANGLE plc ...is pleased to announce that the Edith Cowan University, Perth, Australia, has published results from a study in small cell lung cancer (SCLC) patients using the Parsortix® system. The primary aim of this study was to demonstrate the ability to evaluate the PD-L1 status of isolated circulating tumour cells (CTCs), providing an alternative sample than solid tissue in SCLC, which may help to predict response to immunotherapy."

"ANGLE plc...is pleased to announce that researchers at King's College London, UK, have published data investigating the role of invasive cellular protrusion, known as invadopodia, activity in prostate cancer, and a potential role in the formation of circulating tumour cells (CTCs). This novel finding has the potential to provide a new target, within the metastatic process, for the development of novel therapeutics in the prostate cancer setting...the researchers used ANGLE's marker-independent Parsortix® system to isolate CTCs from prostate cancer patients with a Gleason score ≥7 (medium to high grade cancer)."

"ANGLE plc...is delighted to announce it has signed a master clinical study agreement with Solaris Health Holdings, LLC (Solaris) and joinder agreements with MidLantic Urology LLC, to collaborate and conduct clinical studies in prostate cancer and as a potential route to market in the United States...Together with MidLantic Urology, ANGLE will initiate clinical studies aimed at investigating the use of the Parsortix® system for the detection of prostate cancer and prediction of its severity in patients who present with an elevated prostate specific antigen (PSA) level and/or abnormal digital rectal exam."

"ANGLE plc...is pleased to announce that a leading cancer research institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, has published results of work undertaken in advanced non-small cell lung cancer (NSCLC) and sarcoma patients. The institute demonstrated that the Parsortix® system could successfully isolate circulating tumour cells (CTCs) from frozen peripheral blood mononuclear cell (PBMC) samples."

"ANGLE plc...is absolutely delighted to announce that the US Food and Drug Administration (FDA) has cleared the Parsortix® system for its intended use with metastatic breast cancer (MBC) patients...This ground-breaking FDA clearance is the first ever FDA product clearance to harvest cancer cells from a patient blood sample for subsequent analysis and offers the prospect of a new era of personalised cancer care."

"ANGLE plc...is pleased to announce that Prostate Cancer UK has approved funding for a significant clinical study at Barts Cancer Institute, Queen Mary University of London. The study will investigate the use of the Parsortix® system to isolate circulating tumour cells (CTCs) as a predictor of future disease recurrence. Assessment of whether prostate cancer is likely to progress, if this can be done reliably, may have a major bearing on whether radical prostatectomy surgery is the most appropriate treatment choice...The trial is being funded by a £750,000 grant from Prostate Cancer UK and will follow 200 men with localised prostate cancer over five years."

"ANGLE plc...is pleased to announce that the Company has presented a poster showcasing the Parsortix® system at the American Association for Cancer Research Conference (AACR) 2022, held in New Orleans, United States on 8-13 April 2022...The research presented related to the use of the Parsortix system with triple negative breast cancer (TNBC) patients."

"ANGLE plc...is pleased to announce that the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland, has published results of work undertaken in preclinical models of metastatic breast cancer (MBC), where they have identified specific genes involved in various steps of the metastatic process...This study adds to the growing body of evidence demonstrating the ability of the Parsortix system to isolate single CTCs and CTC clusters, enabling the identification of actionable targets involved in the metastatic spread of cancer. This research has potential clinical applicability in discovering and testing, new and existing, targeted therapies."

"ANGLE plc...is pleased to announce that the University of Maryland Marlene and Stewart Greenebaum NCI Comprehensive Cancer Institute, Baltimore, Maryland, USA, has published results of work undertaken in preclinical models of triple-negative breast cancer (TNBC), showing that isolation of live circulating tumour cells (CTCs) from a simple blood draw, using the Parsortix® system, can provide rapid information on patient response to existing chemotherapy treatments that can target metastasis more effectively than tumour growth."

"ANGLE plc...announce that a leading cancer research institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, has published results of a study undertaken in early stage triple negative breast cancer (TNBC) patients undergoing neoadjuvant chemotherapy (NAC; chemotherapy administered before surgery)...This study demonstrates how CNA analysis of CTCs harvested by the Parsortix system, from early stage TNBC patients pre- and post-NAC treatment, has the potential to provide information on tumour evolution and identify actionable therapeutic targets that could help determine future treatment options for patients with chemotherapy-resistant disease."

"ANGLE plc...provides an update on the accreditation of its clinical laboratory in the United States to allow Parsortix® tests to be offered for patient management...The Centers for Medicare and Medicaid Services (CMS) has issued a Certificate of Registration, under the Clinical Laboratory Improvement Amendments (CLIA), to the Company's United States clinical laboratory. This is a key step towards achieving CLIA accreditation of the laboratory."

"ANGLE plc...is pleased to announce that the Edith Cowan University, Perth, Australia, has published results from a study in ovarian cancer patients using the Parsortix® system. The primary aim of this study was to demonstrate the ability to evaluate the expression of both epithelial and mesenchymal markers, as well as PD-L1 status, of circulating tumour cells (CTCs) isolated using the Parsortix system, which may help to predict whether patients will respond to immunotherapy drugs."

"ANGLE plc...is delighted to announce the publication of breakthrough research undertaken by the world-class team at the University of Southern California Norris Cancer Center. The research demonstrates the potential of circulating tumour cells (CTCs) harvested from a simple blood draw using the Company's Parsortix® system to be used as an alternative to invasive metastatic tissue biopsy for metastatic breast cancer (MBC) patients."